28.28USD+5.07%Mkt Cap: 385.85M USDP/E: —Last update: 2026-06-01
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product c…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap385.85M USD
Enterprise Value358.84M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-15.79M USD
Revenue/Share—
Last Price28.28 USD
Fiscal Year EndDec 2024
MR QuarterSep 2025
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-31.92
PEG—
EV/EBITDA-18.32
EV/Revenue—
P/S—
P/B165.66
EPS (TTM)-1.46
EPS (Forward)-0.82
52W Range
7.78078% of range34.10
52W High34.10 USD
52W Low7.780 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-623.07%
ROA-385.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.27M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-0.35%
Net Debt-3.81M USD
Net Debt/EBITDA0.19
Balance Sheet
Debt/Equity—
Current Ratio2.35
Quick Ratio2.35
Book Value/Sh0.1580 USD
Cash/Share0.2750 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)47.50 USD
Target Range45.00 USD – 50.00 USD
# Analysts2
Ownership
Shares Out.13.85M
Float6.57M
Insiders50.71%
Institutions13.15%
Short Interest
Short Ratio11.1d
Short % Float22.47%
Short % Out.11.13%
Shares Short1.54M
Short (prev mo.)1.52M
Technical
SMA 5024.90 (+13.6%)
SMA 20018.31 (+54.5%)
Beta1.39
S&P 52W Chg27.94%
Avg Vol (30d)128.29K
Avg Vol (10d)119.77K
Technical Indicators
RSI (14)53.9
MACD1.0126
MACD Signal0.7389
MACD Hist.+0.2736
BB Upper30.05 USD
BB Middle25.64 USD
BB Lower21.22 USD
BB Width34.42%
ATR (14)1.985 USD
Vol Ratio (20d)1.11x